Middle East and Africa central precocious puberty (CPP) treatment market is projected to register a CAGR of 5.9% in the forecast period of 2020 to 2027. The new market report contains data for the historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027.
Market Segmentation:
Middle East and Africa Central Precocious Puberty (CPP) Treatment market, By Type (Medication, Surgery), Month (1-Month, 3-Month, 6-Month, Others), Route of Administration (Parenteral, Oral, Implants, Others), Gender (Girls, Boys), End User (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others), Country (South Africa, Saudi Arabia, U.A.E., Israel, Egypt, Kuwait and Rest of Middle East and Africa) Industry Trends and Forecast to 2027

Some of the major factors contributing to the growth of Middle East and Africa central precocious puberty (CPP) treatment market are:

• Increasing cases of granulosa cell tumors
• Increasing prevalence of obesity

Market Players:

The key market players for Middle East and Africa central precocious puberty (CPP) treatment market are listed below:

• Ipsen Pharma
• AbbVie Inc.
• Mylan N.V.
• Pfizer Inc.
• Takeda Pharmaceutical Company Limited
• Sanofi
• AstraZeneca
• Sun Pharmaceutical Industries Ltd